CRM
BIO icon

Cramer Rosenthal McGlynn’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-64,289
Closed -$23M – 105
2023
Q3 		$23M Sell
64,289
-3,286
-5% -$1.27M 1.29% 31
2023
Q2 		$25.6M Sell
67,575
-13,498
-17% -$5.49M 1.28% 32
2023
Q1 		$38.8M Buy
81,073
+2,051
+3% +$960K 1.75% 16
2022
Q4 		$33.2M Buy
79,022
+19,996
+34% +$8.07M 1.46% 23
2022
Q3 		$24.6M Buy
59,026
+13,677
+30% +$6.82M 1.18% 34
2022
Q2 		$22.4M Buy
45,349
+16,838
+59% +$8.77M 1.03% 40
2022
Q1 		$16.1M Sell
28,511
-884
-3% -$533K 0.63% 62
2021
Q4 		$22.2M Sell
29,395
-550
-2% -$412K 0.72% 60
2021
Q3 		$22.3M Sell
29,945
-649
-2% -$486K 0.76% 52
2021
Q2 		$19.7M Sell
30,594
-2,013
-6% -$1.23M 0.63% 63
2021
Q1 		$18.6M Sell
32,607
-18,282
-36% -$10.8M 0.62% 61
2020
Q4 		$29.7M Sell
50,889
-23,492
-32% -$13.4M 0.93% 40
2020
Q3 		$38.3M Sell
74,381
-9,644
-11% -$4.88M 1.55% 25
2020
Q2 		$37.9M Sell
84,025
-63,320
-43% -$27.9M 1.53% 26
2020
Q1 		$51.7M Sell
147,345
-6,733
-4% -$2.48M 2.43% 6
2019
Q4 		$57M Sell
154,078
-13,707
-8% -$4.83M 1.62% 17
2019
Q3 		$55.8M Sell
167,785
-6,220
-4% -$2.03M 1.58% 16
2019
Q2 		$54.4M Sell
174,005
-5,385
-3% -$1.61M 1.49% 19
2019
Q1 		$54.8M Sell
179,390
-21,266
-11% -$5.74M 1.31% 25
2018
Q4 		$46.6M Buy
200,656
+13,798
+7% +$3.7M 1.18% 32
2018
Q3 		$58.5M Sell
186,858
-4,054
-2% -$1.26M 1.12% 32
2018
Q2 		$55.1M Buy
190,912
+39,046
+26% +$10.8M 0.99% 40
2018
Q1 		$38M Buy
151,866
+45,446
+43% +$11.6M 0.62% 75
2017
Q4 		$25.4M Sell
106,420
-170,874
-62% -$41.4M 0.41% 88
2017
Q3 		$61.6M Sell
277,294
-41,648
-13% -$9.37M 0.99% 31
2017
Q2 		$72.2M Buy
318,942
+218,512
+218% +$47.6M 1.1% 23
2017
Q1 		$20M Buy
+100,430
New +$19.3M 0.31% 112

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cramer Rosenthal McGlynn's BIO Position: Q4 2023 in Review

Cramer Rosenthal McGlynn sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 64,289 shares — an estimated $23M sold.

Cramer Rosenthal McGlynn first reported a position in BIO in Q1 2017 and held it in 27 quarters. The position peaked at $72.2M in Q2 2017. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Cramer Rosenthal McGlynn reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Cramer Rosenthal McGlynn sold 64,289 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $23M.
  • Cramer Rosenthal McGlynn first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and held it in 27 quarters.
  • Cramer Rosenthal McGlynn's Bio-Rad Laboratories Class A position peaked at $72.2M in Q2 2017.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Cramer Rosenthal McGlynn's 13F filing for Q4 2023, filed 13 Feb 2024.